| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $234,558,035 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35CA304457 | Understanding and Targeting Aberrant RNA Splicing in Leukemia | 000 | 1 | NIH | 8/15/2025 | $1,034,176 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA304010 | Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer | 000 | 1 | NIH | 8/15/2025 | $730,398 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 001 | 6 | NIH | 5/28/2025 | $37,559 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 000 | 6 | NIH | 3/12/2025 | $338,027 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | P01CA275746 | Leveraging Observational (Real World) Data to Advance Precision Oncology | 000 | 2 | NIH | 9/5/2025 | $2,357,014 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA285856 | Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma | 000 | 2 | NIH | 6/26/2025 | $544,255 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA286566 | A Mechanoimmunological Basis for Metastatic Site Preference | 000 | 2 | NIH | 7/31/2025 | $558,034 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA263967 | Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | 000 | 5 | NIH | 5/8/2025 | $727,406 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD008181 | Phase II trial of avutometinib plus defactinib in RAF dimer-driven thyroid cancers | 000 | 2 | FDA | 7/11/2025 | $194,528 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R50CA265328 | Developing therapeutic TCR mimic monoclonal antibodies for cancer | 000 | 4 | NIH | 8/19/2025 | $135,201 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA283041 | Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigation | 003 | 2 | NIH | 9/24/2025 | $1,249 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA283041 | Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigation | 002 | 2 | NIH | 9/22/2025 | -$1,249 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01HG014186 | Approaches for engineering transcriptional state of fibroblasts and other differentiated cell types | 000 | 1 | NIH | 9/22/2025 | $789,739 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F99CA294267 | Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells. | 001 | 2 | NIH | 8/15/2025 | $52,538 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F99CA294267 | Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells. | 000 | 1 | NIH | 1/28/2025 | $3,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 3 | NIH | 2/28/2025 | $268,826 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248289 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | 002 | 6 | NIH | 9/12/2025 | -$465,168 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248289 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | 000 | 6 | NIH | 3/3/2025 | $545,622 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 002 | 4 | NIH | 5/28/2025 | $122,908 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 4 | NIH | 4/28/2025 | $1,101,453 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 001 | 6 | NIH | 5/30/2025 | $28,481 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 000 | 6 | NIH | 3/3/2025 | $256,330 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 1 | NIH | 1/30/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01HG012103 | Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune Inflammation | 001 | 5 | NIH | 7/28/2025 | $1,254,399 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297030 | Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | 000 | 1 | NIH | 2/25/2025 | $145,336 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1HL069315 | BMT Core - MSK | 001 | 25 | NIH | 7/16/2025 | $264,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 000 | 1 | NIH | 3/11/2025 | $700,611 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 002 | 2 | NIH | 7/15/2025 | -$116,356 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 001 | 2 | NIH | 6/17/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 2 | NIH | 2/18/2025 | $135,224 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA252633 | Behavioral Activation for Depression in Older Adult Cancer Survivors: Pilot Randomized Control Trial and Implementation Outcomes | 000 | 5 | NIH | 2/28/2025 | $174,699 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 001 | 2 | NIH | 9/9/2025 | $69,614 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 000 | 2 | NIH | 3/13/2025 | $626,533 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300788 | Inflammatory Signaling in the Leptomeninges | 000 | 1 | NIH | 3/11/2025 | $730,398 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 001 | 4 | NIH | 4/25/2025 | $72,522 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 4 | NIH | 2/18/2025 | $652,690 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA245471 | Investigating the Role of Cell Plasticity in Malignant Transformation | 000 | 6 | NIH | 2/18/2025 | $106,030 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 001 | 5 | NIH | 5/22/2025 | $44,073 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK132518 | Control of Intestinal Epithelial Function through Lymphatic-Intestinal Stem Cell Communication | 001 | 4 | NIH | 2/25/2025 | $167,617 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 000 | 5 | NIH | 2/14/2025 | $396,645 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 1 | NIH | 2/24/2025 | $205,700 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 002 | 3 | NIH | 5/22/2025 | $65,164 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 001 | 3 | NIH | 2/28/2025 | $586,485 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 5 | NIH | 4/29/2025 | $24,899 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 000 | 5 | NIH | 3/6/2025 | $224,101 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 001 | 5 | NIH | 5/28/2025 | $62,218 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 5 | NIH | 2/19/2025 | $559,979 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 5 | NIH | 2/25/2025 | $688,546 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
|
